861 related articles for article (PubMed ID: 16368266)
1. Mechanism of action of memantine.
Johnson JW; Kotermanski SE
Curr Opin Pharmacol; 2006 Feb; 6(1):61-7. PubMed ID: 16368266
[TBL] [Abstract][Full Text] [Related]
2. The chemical biology of clinically tolerated NMDA receptor antagonists.
Chen HS; Lipton SA
J Neurochem; 2006 Jun; 97(6):1611-26. PubMed ID: 16805772
[TBL] [Abstract][Full Text] [Related]
3. Potency, voltage-dependency, agonist concentration-dependency, blocking kinetics and partial untrapping of the uncompetitive N-methyl-D-aspartate (NMDA) channel blocker memantine at human NMDA (GluN1/GluN2A) receptors.
Gilling KE; Jatzke C; Hechenberger M; Parsons CG
Neuropharmacology; 2009 Apr; 56(5):866-75. PubMed ID: 19371579
[TBL] [Abstract][Full Text] [Related]
4. Activation of brain histaminergic neurotransmission: a mechanism for cognitive effects of memantine in Alzheimer's disease.
Motawaj M; Burban A; Davenas E; Arrang JM
J Pharmacol Exp Ther; 2011 Feb; 336(2):479-87. PubMed ID: 21057059
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological implications of two distinct mechanisms of interaction of memantine with N-methyl-D-aspartate-gated channels.
Chen HS; Lipton SA
J Pharmacol Exp Ther; 2005 Sep; 314(3):961-71. PubMed ID: 15901795
[TBL] [Abstract][Full Text] [Related]
6. In vitro galantamine-memantine co-application: mechanism of beneficial action.
Zhao X; Marszalec W; Toth PT; Huang J; Yeh JZ; Narahashi T
Neuropharmacology; 2006 Dec; 51(7-8):1181-91. PubMed ID: 17011596
[TBL] [Abstract][Full Text] [Related]
7. [New therapeutic possibilities with low-affinity NMDA receptor antagonists].
Kornhuber J; Weller M
Nervenarzt; 1996 Jan; 67(1):77-82. PubMed ID: 8676993
[TBL] [Abstract][Full Text] [Related]
8. [Glutamate-related excitotoxicity neuroprotection with memantine, an uncompetitive antagonist of NMDA-glutamate receptor, in Alzheimer's disease and vascular dementia].
Tanović A; Alfaro V
Rev Neurol; 2006 May 16-31; 42(10):607-16. PubMed ID: 16703529
[TBL] [Abstract][Full Text] [Related]
9. Alzheimer's disease and the glutamate NMDA receptor.
Doraiswamy PM
Psychopharmacol Bull; 2003; 37(2):41-9. PubMed ID: 14566213
[TBL] [Abstract][Full Text] [Related]
10. Pharmacology of acetylcholinesterase inhibitors and N-methyl-D-aspartate receptors for combination therapy in the treatment of Alzheimer's disease.
Geerts H; Grossberg GT
J Clin Pharmacol; 2006 Jul; 46(7 Suppl 1):8S-16S. PubMed ID: 16809810
[TBL] [Abstract][Full Text] [Related]
11. The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence.
Danysz W; Parsons CG
Int J Geriatr Psychiatry; 2003 Sep; 18(Suppl 1):S23-32. PubMed ID: 12973747
[TBL] [Abstract][Full Text] [Related]
12. Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond.
Lipton SA
Nat Rev Drug Discov; 2006 Feb; 5(2):160-70. PubMed ID: 16424917
[TBL] [Abstract][Full Text] [Related]
13. [Role of magnesium ions on the regulation of NMDA receptor--a pharmacopathology of memantine].
Kato T
Clin Calcium; 2004 Aug; 14(8):76-80. PubMed ID: 15577101
[TBL] [Abstract][Full Text] [Related]
14. The NMDA receptor complex: a long and winding road to therapeutics.
Wood PL
IDrugs; 2005 Mar; 8(3):229-35. PubMed ID: 15772895
[TBL] [Abstract][Full Text] [Related]
15. Neuropathologic changes in Alzheimer's disease: potential targets for treatment.
Wenk GL
J Clin Psychiatry; 2006; 67 Suppl 3():3-7; quiz 23. PubMed ID: 16649845
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy of memantine in the treatment of Alzheimer's disease].
Molinuevo Guix JL; Lladó Plarrumaní A
Neurologia; 2005 Dec; 20(10):686-91. PubMed ID: 16317590
[TBL] [Abstract][Full Text] [Related]
17. [Ketamine inhibits n-methyl-d-aspartate (NMDA) receptor mediated acetylcholine release from rabbit caudate nucleus slices].
Feuerstein TJ
Anaesthesist; 1994 Nov; 43 Suppl 2():S48-51. PubMed ID: 7840414
[TBL] [Abstract][Full Text] [Related]
18. Differences in degree of trapping of low-affinity uncompetitive N-methyl-D-aspartic acid receptor antagonists with similar kinetics of block.
Mealing GA; Lanthorn TH; Murray CL; Small DL; Morley P
J Pharmacol Exp Ther; 1999 Jan; 288(1):204-10. PubMed ID: 9862772
[TBL] [Abstract][Full Text] [Related]
19. The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism.
Lipton SA
Curr Alzheimer Res; 2005 Apr; 2(2):155-65. PubMed ID: 15974913
[TBL] [Abstract][Full Text] [Related]
20. Psychotogenicity and N-methyl-D-aspartate receptor antagonism: implications for neuroprotective pharmacotherapy.
Kornhuber J; Weller M
Biol Psychiatry; 1997 Jan; 41(2):135-44. PubMed ID: 9018383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
